US4650858A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Concentrate of the antihemophilic factor VIII and a process for producing it
Assignee: Nordisk Gentofte AS
•
Filing: 1984-03-20
•
Granted: 1987-03-17
•
Expires: 2004-03-20
Abstract
Abstract PCT No. PCT/DK84/00019 Sec. 371 Date Oct. 30, 1984 Sec. 102(e) Date Oct. 30, 1984 PCT Filed Mar. 20, 1984 PCT Pub. No. WO84/03628 PCT Pub. Date Sep. 27, 1984.Production of a high purity concentrate of the antihemophilic Factor VIII (AHF) by precipitation of an aqueous solution of cryoprecipitate from blood plasma in a first step with such an amount of polyethylene glycol (PEG), preferably about 4% by weight, as will precipitate a substantial amount of the present fibrinogen, subjecting the fibrinogen-free solution to a second precipitation step with preferably about 12% by weight of PEG in the presence of a salting-in agent, such as an amino acid, in particular lysine or arginine, or a carbohydrate, and then recovering the precipitate with a concentrated content of the present Factor VIII. The obtained Factor VIII concentrate with a very low content of immunoglobulins and other plasma proteins has a solubility in an aqueous injection medium of 45 to 500 units/ml and a high specific activity of up to 50 units/mg protein.
Inventors
- 👤 Mirella E. Rasmussen
- 👤 Ole Nordfang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 21:56
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/14; A61L; A61L2/00; A61L2/02; A61L2/04; C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A61K38/00; A61L2103/00; A61L2103/05; A61L2103/09; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
158 words
A process for producing an AHF concentrate substantially free of denatured AHF and immunoglobulins and having a solubility in an aqueous injection medium of from 200 to 500 units AHF/ml and a specific activity of from 3.85 to 50 units AHF/mg protein which comprises subjecting a solution of a cryoprecipitate from blood plasma to the following treatment steps: (a) removal of prothrombin present, (b) a first treatment with from 2 to 6% by weight of PEG 200-20,000 thereby to precipitate a substantial amount of the fibrinogen present, (c) a second treatment of the supernatant from the first PEG precipitation with from 6 to 20% by weight of PEG 200 to 20,000 in the presence of an effective amount of a salting-in agent selected from the group consisting of amino acids, carbohydrates and sugar alcohols thereby to precipitate the AHF while essentially keeping the other proteins present in solution, (d) recovering the precipitate having a concentrated content of AHF.
Claim 2
Dependent Claim
158 words
A process for producing an AHF concentrate substantially free of denatured AHF and immunoglobulins and having a solubility in an aqueous injection medium of from 200 to 500 units AHF/ml and a specific activity of from 3.85 to 50 units AHF/mg protein which comprises subjecting a solution of a cryoprecipitate from blood plasma to the following treatment steps: (a) removal of prothrombin present, (b) a first treatment with from 2 to 6% by weight of PEG 200-20,000 thereby to precipitate a substantial amount of the fibrinogen present, (c) a second treatment of the supernatant from the first PEG precipitation with from 6 to 20% by weight of PEG 200 to 20,000 in the presence of an effective amount of a salting-in agent selected from the group consisting of amino acids, carbohydrates and sugar alcohols thereby to precipitate the AHF while essentially keeping the other proteins present in solution, (d) recovering the precipitate having a concentrated content of AHF.
Claim 3
Dependent Claim
21 words
A process according to claim 1, wherein the salting-in agent used in the second precipitation step is a basic amino acid.
Claim 4
Dependent Claim
14 words
A process according to claim 2, wherein the salting-in agent is lysine or arginine.
Claim 5
Dependent Claim
24 words
A process according to claim 1, wherein the salting-in agent used in the second precipitation step is a carbohydrate selected from mono- and disaccharides.
Claim 6
Dependent Claim
12 words
A process according to claim 4, wherein the salting-in agent is saccharose.
Claim 7
Dependent Claim
26 words
A process according to claim 4, wherein PEG is added in the first precipitation step until a concentration of about 4% by weight of the solution.
Claim 8
Dependent Claim
25 words
A process according to claim 4, wherein PEG is added in the second precipitation step corresponding to a total concentration of about 12% by weight.
Claim 9
Dependent Claim
29 words
A process according to claim 3, wherein lysine or arginine is added in the second precipitation step in an amount corresponding to a concentration of 0.1 to 0.9 mole/l.
Claim 10
Dependent Claim
28 words
A process according to claim 8, wherein the pH in the first precipitation step is 6.0 to 8.5 and in the second precipitation step is 5.0 to 8.5.
Claim 11
Dependent Claim
37 words
A process according to claim 9, wherein the recovered Factor VIII concentrate is heated to 60° C. for at least 10 hours in the presence of a suitable stabilizer so as to provide a safeguard against hepatitis.
Claim 12
Dependent Claim
14 words
A process according to claim 10, wherein the recovered Factor VIII concentrate is freeze-dried.
Claim 13
Dependent Claim
21 words
A process according to claim 8, wherein lysine or arginine is added in an amount corresponding to 0.3 to 0.8 mole/l.
Claim 14
Dependent Claim
28 words
A process according to claim 9, wherein the pH in the first precipitation step is 6.2 to 6.6 and in the second precipitation step is 6.0 to 6.6.
Claim 15
Dependent Claim
26 words
A process according to claim 13, wherein the pH in the first precipitation step is about 6.4 and in the second precipitation step is about 6.3.
References Cited (Backward Citations)
US3652530A
Cited
US3631018A
Cited
US3682881A
Cited
US4069216A
Cited
US4027013A
Cited
US4093608A
Cited
DE2715832A1
Cited
EP0018561A2
Cited
US4297344A
Cited
US4387092A
Cited
FR2460305A2
Cited
EP0032655A1
Cited
US4348315A
Cited
US4289691A
Cited
US4455301A
Cited
GB2083047A
Cited
US4404131A
Cited
US4465574A
Cited
US4435318A
Cited
US4446134A
Cited
US4361509A
Cited
US4495175A
Cited
US4478825A
Cited
US4508709A
Cited
US4486410A
Cited
US4543210A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-03-16 | 1990-09-15 | 1991-03-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-03-16 | 1994-09-15 | 1995-03-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-03-16 | 1998-09-15 | 1999-03-17 | $7700.00 | Window Closed / Lapsed |